2023
Multimodal immunogenomic biomarker analysis of tumors from pediatric patients enrolled to a phase 1-2 study of single-agent atezolizumab
Nabbi A, Danesh A, Espin-Garcia O, Pedersen S, Wellum J, Fu L, Paulson J, Geoerger B, Marshall L, Trippett T, Rossato G, Pugh T, Hutchinson K. Multimodal immunogenomic biomarker analysis of tumors from pediatric patients enrolled to a phase 1-2 study of single-agent atezolizumab. Nature Cancer 2023, 4: 502-515. PMID: 37038005, PMCID: PMC10132976, DOI: 10.1038/s43018-023-00534-x.Peer-Reviewed Original ResearchConceptsPediatric patientsAssociated with progression-free survivalCD8+ T cellsT cell receptor repertoireProgression-free survivalImmune-checkpoint inhibitionB cell infiltrationTertiary lymphoid structuresBiomarker analysisAtezolizumab therapyAntitumor immunityStable diseasePD-L1Partial responseTumor neoantigensRefractory tumorsPatient tumorsLymphoid structuresT cellsB cellsReceptor repertoireClinical trialsClinical activityTumorImmune response
2022
mirTarRnaSeq: An R/Bioconductor Statistical Package for miRNA-mRNA Target Identification and Interaction Analysis
Movassagh M, Morton S, Hehnly C, Smith J, Doan T, Irizarry R, Broach J, Schiff S, Bailey J, Paulson J. mirTarRnaSeq: An R/Bioconductor Statistical Package for miRNA-mRNA Target Identification and Interaction Analysis. BMC Genomics 2022, 23: 439. PMID: 35698050, PMCID: PMC9191533, DOI: 10.1186/s12864-022-08558-w.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionLung epithelial cellsEpithelial cellsHuman lung epithelial cellsSARS-CoV-2NK cellsStatistical PackageEBV miRNAsT cellsImmune pathwaysB cellsClinical relevanceSample cohortCD34 cellsStomach adenocarcinomaEndothelial cellsTime pointsInfectionCOVID-19CellsCD4AdenocarcinomaPatientsCD19Cytokines
2019
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Sehn L, Herrera A, Flowers C, Kamdar M, McMillan A, Hertzberg M, Assouline S, Kim T, Kim W, Ozcan M, Hirata J, Penuel E, Paulson J, Cheng J, Ku G, Matasar M. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Journal Of Clinical Oncology 2019, 38: 155-165. PMID: 31693429, PMCID: PMC7032881, DOI: 10.1200/jco.19.00172.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBendamustine HydrochlorideBiomarkers, TumorFemaleHumansImmunoconjugatesImmunohistochemistryLymphoma, Large B-Cell, DiffuseMaleMiddle AgedProgression-Free SurvivalSurvival RateConceptsProgression-free survivalLarge B-cell lymphomaPolatuzumab vedotinB-cell lymphomaCR rateOverall survivalPola-BRR/R DLBCLRefractory diffuse large B-cell lymphomaIRC-assessed progression-free survivalDiffuse large B-cell lymphomaB-cell receptor componentsSingle-arm cohortsDuration of responseCohort of patientsCox regression methodRisk of deathMedian OSSafety profileKaplan-MeierTreatment optionsB cellsPolatuzumabBendamustineDLBCL